Literature DB >> 8788072

Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies.

J Kornhuber1, C G Parsons, S Hartmann, W Retz, S Kamolz, J Thome, P Riederer.   

Abstract

Orphenadrine has been used as an antiparkinsonian, antispastic and analgesic drug for many years. Here we show that orphenadrine inhibits [3H]MK-801 binding to the phencyclidine (PCP) binding site of the N-methyl-D-aspartate (NMDA)-receptor in homogenates of postmortem human frontal cortex with a Ki-value of 6.0 +/- 0.7 microM. The NMDA receptor antagonistic effects of orphenadrine were assessed using concentration- and patch-clamp techniques on cultured superior colliculus neurones. Orphenadrine blocked open NMDA receptor channels with fast kinetics and in a strongly voltage-dependent manner. The IC50-value against steady state currents at -70 mV was 16.2 +/- 1.6 microM (n = 6). Orphenadrine exhibited relatively fast, concentration-dependent open channel blocking kinetics (Kon 0.013 +/- 0.002 10(6) M-1S-1) whereas the offset rate was concentration-independent (Koff 0.230 +/- 0.004 S-1). Calculation of the ratio Koff/Kon revealed an apparent Kd-value of 17.2 microM which is nearly identical to the IC50 calculated at equilibrium.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8788072     DOI: 10.1007/bf01281158

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  29 in total

Review 1.  Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia.

Authors:  P Riederer; K W Lange; J Kornhuber; W Danielczyk
Journal:  Arzneimittelforschung       Date:  1992-02

Review 2.  Behavioural pharmacology of glutamate in the basal ganglia.

Authors:  W J Schmidt; M Bubser; W Hauber
Journal:  J Neural Transm Suppl       Date:  1992

Review 3.  Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease.

Authors:  M Carlsson; A Carlsson
Journal:  Trends Neurosci       Date:  1990-07       Impact factor: 13.837

4.  Effects of antiparkinsonian drugs on muscarinic receptor binding in rat brain, heart and lung.

Authors:  E K Syvälahti; R Kunelius; L Laurén
Journal:  Pharmacol Toxicol       Date:  1988-02

5.  Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism.

Authors:  R H Mindham; R Gaind; B H Anstee; L Rimmer
Journal:  Psychol Med       Date:  1972-11       Impact factor: 7.723

6.  Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine.

Authors:  C G Parsons; V A Panchenko; V O Pinchenko; A Y Tsyndrenko; O A Krishtal
Journal:  Eur J Neurosci       Date:  1996-03       Impact factor: 3.386

7.  Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study.

Authors:  J Kornhuber; J Bormann; M Hübers; K Rusche; P Riederer
Journal:  Eur J Pharmacol       Date:  1991-04-25       Impact factor: 4.432

8.  Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro.

Authors:  A Lupp; C H Lücking; R Koch; R Jackisch; T J Feuerstein
Journal:  J Pharmacol Exp Ther       Date:  1992-11       Impact factor: 4.030

9.  Suppression by memantine and amantadine of synaptic excitation intrastriatally evoked in rat neostriatal slices.

Authors:  J Rohrbacher; M Bijak; U Misgeld
Journal:  Neurosci Lett       Date:  1994-11-21       Impact factor: 3.046

Review 10.  Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties.

Authors:  J Kornhuber; M Weller; K Schoppmeyer; P Riederer
Journal:  J Neural Transm Suppl       Date:  1994
View more
  5 in total

1.  Orphenadrine prevents 3-nitropropionic acid-induced neurotoxicity in vitro and in vivo.

Authors:  D Pubill; E Verdaguer; A M Canudas; F X Sureda; E Escubedo; J Camarasa; M Pallàs; A Camins
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

Review 2.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats.

Authors:  Katherine L Nicholson; Robert L Balster
Journal:  Psychopharmacology (Berl)       Date:  2003-07-08       Impact factor: 4.530

4.  Anticholinergic antiparkinson drug orphenadrine inhibits HERG channels: block attenuation by mutations of the pore residues Y652 or F656.

Authors:  Eberhard P Scholz; Franziska M Konrad; Daniel L Weiss; Edgar Zitron; Claudia Kiesecker; Ramona Bloehs; Martin Kulzer; Dierk Thomas; Sven Kathöfer; Alexander Bauer; Martin H Maurer; Gunnar Seemann; Hugo A Katus; Christoph A Karle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-27       Impact factor: 3.000

5.  Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia: role of M1 muscarinic receptors.

Authors:  Marta Maltese; Giuseppina Martella; Graziella Madeo; Irene Fagiolo; Annalisa Tassone; Giulia Ponterio; Giuseppe Sciamanna; Pierre Burbaud; P Jeffrey Conn; Paola Bonsi; Antonio Pisani
Journal:  Mov Disord       Date:  2014-09-04       Impact factor: 10.338

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.